Planetary raises CHF 22 million to scale mycoprotein platform across Europe

Planetary pulled together a financing package that adds CHF 22 million in fresh capital and brings its total funding to about CHF 32 million, a signal that investors still see room for a fermentation platform built around industrial side streams, not just finished foods. The Swiss company said the round was led by Radikal Capital and Oetker Ventures, with backing from Royal Cosun, arc investors, Green Generation Fund, AgriFoodTech Venture Alliance, Astanor Ventures and XAnge. A second closing was planned for later in the summer.

What makes the deal stand out is the structure. Planetary raised CHF 16 million in Series A equity and added CHF 6 million in credit, a mix that points to a company trying to finance both industrial buildout and commercialization. Planetary SA describes itself as a Swiss-based full-stack fermentation company building the industrial backbone of the bioeconomy, and its BioBlocks™ platform is protected by patents and trademarks. The pitch is straightforward: let sugar producers turn waste into value through licensing, then use that feedstock logic to produce food ingredients with real functional use.

That platform story now has a retail proof point. Planetary launched vegan mycoprotein filet products at ALDI Suisse in April 2026 at price parity with conventional chicken, giving the company an immediate market test beyond the licensing slide deck. A sustainability listing for a BioBlocks process run at Konica Minolta in Aarberg, Switzerland said the system reduced cost of goods sold by 20 percent to 30 percent, a detail that matters in a sector where scale usually gets judged on economics before it gets judged on excitement.

The investor mix also suggests a pragmatic reading of the category. Royal Cosun had already invested CHF 3 million in January 2025, making the sugar-sector participant’s return a notable endorsement of Planetary’s feedstock strategy. For a company that says it plans to double capacity in 2026 and expand across Europe, Asia and the Americas, the message is that mycoprotein can be more than a branded product play. It can be an industrial model that converts circular inputs into ingredient supply, while leaving room for direct sales, licensing, and broader European expansion.